Sanna Turunen

Sanna Turunen

Auto-generated profile, based on publicly available information

Sanna Turunen

Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MPMaria Persson
Maria Persson
PLPetri P. Lehenkari
Petri P. Lehenkari
LBLena Berglin
Lena Berglin
STSanna Turunen
Sanna Turunen
MFMikko A. J. Finnilä
Mikko A. J. Finnilä
JTJuha Tuukkanen
Juha Tuukkanen
Fiber-based scaffolds produced by textile manufacturing technology offer versatile materials for tissue engineering applications since a wide range of crucial scaffold parameters, including porosity, pore size and interconnectivity, can be accurately controlled using 3D weaving. In this study, we developed a weavable, bioactive biodegradable composite fiber from poly (lactic acid) (PLA) and hydroxyapatite powder by melt spinning. Subsequently, scaffolds of these fibers were fabricated by 3D weaving. The differentiation of human mesenchymal stem cells (hMSCs)in vitrowas studied on the 3D scaffolds and compared with differentiation on 2D substrates having the same material composition. Our data showed that the 3D woven scaffolds have a major impact on hMSCs proliferation and activation. The 3D architecture supports the differentiation of the hMSCs into osteoblast cells and enhances the production of mineralized bone matrix. The present study further confirms that a 3D scaffold promotes hMSCs differentiation into the osteoblast–lineage and bone mineralization.

22 May 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
AMAnne-Mari Mustonen
Anne-Mari Mustonen
RKReijo Käkelä
Reijo Käkelä
PLPetri Lehenkari
Petri Lehenkari
JHJohanna Huhtakangas
Johanna Huhtakangas
STSanna Turunen
Sanna Turunen
PNPetteri Nieminen
Petteri Nieminen
Infrapatellar fat pad (IFP) has recently emerged as a potential source of inflammation in knee arthropathies. It has been proposed to be one source of adipocytokines, fatty acids (FA), and FA-derived lipid mediators that could contribute to the pathophysiological processes in the knee joint. Alterations in synovial fluid (SF) lipid composition have been linked to both osteoarthritis (OA) and rheumatoid arthritis (RA). The aim of the present study was to compare the FA signatures in the IFP and SF of RA and OA patients. Pairs of IFP and SF samples were collected from the same knees of RA (n = 10) and OA patients (n = 10) undergoing total joint replacement surgery. Control SF samples (n = 6) were harvested during diagnostic or therapeutic arthroscopic knee surgery unrelated to RA or OA. The FA composition in the total lipids of IFP and SF was determined by gas chromatography with flame ionization and mass spectrometric detection. Arthropathies resulted in a significant reduction in the SF proportions of n-6 polyunsaturated FA (PUFA), more pronouncedly in OA than in RA. OA was also characterized with reduced percentages of 22:6n-3 and lower product/precursor ratios of n-3 PUFA. The proportions of total monounsaturated FA increased in both RA and OA SF. Regarding IFP, RA patients had lower proportions of 20:4n-6, total n-6 PUFA, and 22:6n-3, as well as lower product/precursor ratios of n-3 PUFA compared to OA patients. The average chain length of SF FA decreased in both diagnoses and the double bond index in OA. The observed complex alterations in the FA signatures could have both contributed to but also limited the inflammatory processes and cartilage destruction in the RA and OA knees.

20 October 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
STSanna Turunen
Sanna Turunen
JHJohanna Huhtakangas
Johanna Huhtakangas
TNTomi Nousiainen
Tomi Nousiainen
MVMaarit Valkealahti
Maarit Valkealahti
JMJukka Melkko
Jukka Melkko
PLPetri Lehenkari
Petri Lehenkari
Seropositive rheumatoid arthritis (RA) is characterized by autoantibodies binding to citrullinated and homocitrullinated proteins. We wanted to study the expression patterns of these disease-associated protein forms and if the rheumatoid nodule and synovial tissue itself contain biologically active levels of citrullinating peptidyl arginine deiminases 2, 3 and 4 and homocitrullination-facilitating neutrophil enzyme myeloperoxidase. Total of 195 synovial samples from metatarsal joints from five ACPA/RF-positive RA patients (n = 77), synovial samples from knees of eight seropositive RA (n = 60), seven seronegative RA (n = 33) and five osteoarthritis (n = 25) patients were analyzed for citrulline and homocitrulline contents using HPLC. The location of citrulline- and homocitrulline-containing proteins, PAD 2, 3, 4 and myeloperoxidase were shown by immunostaining. Myeloperoxidase and citrulline- or homocitrulline-containing proteins were stained on Western blot. Overall, necrosis was frequent in metatarsals of seropositive RA and absent in seronegative RA and osteoarthritis patients. In histological analysis, there was a significant local patterning and variation in the citrulline and homocitrulline content and it was highest in metatarsal synovial tissues of seropositive RA patients. We found peptidyl arginine deiminase 2, 3 and 4 in the lining and sublining layers of intact synovial tissue. Myeloperoxidase was found locally around necrotic areas. The tissues with necrosis contained the highest levels of citrulline and homocitrulline. Rheumatoid nodules and synovia contain significant amount of PAD2, 3 and 4 and myeloperoxidase enzymes. These enzymes could explain the levels of citrulline and homocitrulline in seropositive RA synovial and rheumatoid nodule tissues especially around necrotic tissue.

8 July 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
STSanna Turunen
Sanna Turunen
MKMarja-Kaisa Koivula
Marja-Kaisa Koivula
LRLeila Risteli
Leila Risteli
JRJuha Risteli
Juha Risteli
Objective To clarify the possible roles of protein-bound homocitrulline in causing an antibody response to citrulline and as a confounding factor in citrulline detection assays. Methods Native, carbamoylated, and citrullinated albumins were used for testing the specificity of commercial antibodies against modified citrulline by Western blot. Rabbits were immunized with human albumin and/or bone type I collagen, both of which were treated with cyanate to produce homocitrulline, or with citrullinated synthetic telopeptide of type I collagen. These antisera were tested for binding to cyclic citrullinated peptide 2 (CCP-2), mutated citrullinated vimentin, and type I or II collagen telopeptides containing either citrulline or homocitrulline. Results Commercial antibodies that had been considered to be specific for chemically modified citrulline were found to recognize both homocitrulline- and citrulline-containing albumins. The rabbits immunized with proteins containing homocitrulline produced high-affinity antibodies against CCP-2 and, to a lesser extent, against mutated citrullinated vimentin. The antisera also bound homocitrulline-containing collagen telopeptides and, less strongly, citrulline-containing telopeptides. Conclusion Our findings demonstrate that homocitrulline, which is a structural analog of citrulline (longer by 1 carbon, and readily formed in the body), can be involved in raising citrulline-recognizing antibodies in experimental animals and can cause false-positive reactions in assays for citrulline.

1 September 2018 in Heliyon
Verified
Journal Article
Open access
EKElina Kylmäoja
Elina Kylmäoja
MNMiho Nakamura
Miho Nakamura
STSanna Turunen
Sanna Turunen
CPChristina Patlaka
Christina Patlaka
GAGöran Andersson
Göran Andersson
JTJuha Tuukkanen
Juha Tuukkanen
Bone marrow (BM) and peripheral blood (PB) derived mononuclear cells are precursors of in vitro osteoclast differentiation. However, few studies have compared the phenotypic and functional properties of osteoclasts generated from these sources and the effects of different growth factors on osteoclastogenesis. Both cell types differentiated into functional osteoclasts, but culturing the cells with or without transforming growth factor beta (TGF-β) and dexamethasone revealed differences in their osteoclastogenic capacity. When receptor activator for nuclear factor κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) were used for differentiation, we did not observe differences in bone resorption activity or expression of osteoclastogenic genes calcitonin receptor (CR) and nuclear factor of activated T-cells (NFATc1) between the osteoclasts formed from the two sources. Addition of TGF-β and dexamethasone led to higher number of nuclei in multinuclear cells and increased expression of tartrate resistant acid phosphatase (TRACP) 5a and 5b, CR and NFATc1 in PB- derived osteoclasts depicting the higher osteoclastogenic potential and responsiveness to TGF-β and dexamethasone in PB monocytes. These results conclude that the choice of the osteoclast precursor source as well as the choice of osteoclastogenic growth factors are essential matters in determining the phenotypic characteristics of heterogeneous osteoclast populations.

1 October 2017 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
JHJohanna A. Huhtakangas
Johanna A. Huhtakangas
JVJohanna Veijola
Johanna Veijola
STSanna Turunen
Sanna Turunen
AKAnna Karjalainen
Anna Karjalainen
MVMaarit Valkealahti
Maarit Valkealahti
PLPetri Lehenkari
Petri Lehenkari